KVH Industries Inc
Change company Symbol lookup
Select an option...
KVHI KVH Industries Inc
BHC Bausch Health Companies Inc
ANPC AnPac Bio-Medical Science Co Ltd
TREX Trex Company Inc
VIVO Meridian Bioscience Inc
WASH Washington Trust Bancorp Inc
AWF AllianceBernstein Global High Income Fund Inc.
AVK Advent Convertible & Income Fund
AVK Advent Convertible & Income Fund
AVB Avalonbay Communities Inc
Go

Information Technology : Communications Equipment | Small Cap Blend
Company profile

KVH Industries, Inc. is a manufacturer of solutions that provide high-speed Internet, television and voice services through satellite to mobile users at sea and on land. The Company also provides commercially licensed entertainment, including news, sports, music and movies, to commercial and leisure customers in the maritime, hotel and retail markets. It operates in two geographic segments, in the mobile communications, navigation and guidance and stabilization equipment industry. The Company develops and distributes training films and e-learning computer-based training courses to commercial maritime customers. It is also a manufacturer of navigational sensors and integrated inertial systems for defense and commercial guidance and stabilization applications. It designs, develops, manufactures and markets mobile communications products and services for the marine and land mobile markets, and navigation, guidance and stabilization products for both the commercial and defense markets.

Premarket

Last Trade
Delayed
$9.20
0.04 (0.44%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$9.16
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
211

10-day average volume:
29,045
211

Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020

4:05 pm ET August 4, 2020 (PR Newswire) Print

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2020.

https://mma.prnewswire.com/media/268592/invitae_corporation_logo.jpg

"While we experienced significant disruptions in the healthcare system due to the pandemic, we quickly established a solid recovery during the quarter. Our results highlight the strength of our operations and the benefits of our diversified menu, investments in telehealth capabilities and longstanding customer relationships, all of which position us to adapt and meet the changing needs of our customers," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. "We exited the quarter with a strong footing and increasing momentum. We remain confident in our ability to continue to deliver on our mission to bring genetic information into mainstream medicine."

Second Quarter 2020 Financial Results

-- Accessioned more than 120,000 samples in the second quarter of 2020 compared to 111,000 samples in the second quarter of 2019. Billable volume exceeded 113,000 in the second quarter of 2020

-- Generated revenue of $46.2 million in the second quarter of 2020 compared to $53.5 million in revenue in the second quarter of 2019

-- Reported average cost per sample of $358 in the second quarter of 2020 compared to $252 average cost per sample in the second quarter of 2019. Non-GAAP average cost per sample was $318 in the second quarter of 2020

-- Achieved gross profit of $3.2 million in the second quarter of 2020 compared to $25.5 million of gross profit in the second quarter of 2019. Non-GAAP gross profit was $8.0 million in the second quarter of 2020

Total operating expense, excluding cost of revenue, for the second quarter of 2020 was $145.3 million. Non-GAAP operating expense was $105.7 million in the second quarter of 2020.

Net loss for the second quarter of 2020 was $166.4 million, or $1.29 net loss per share, compared to a net loss of $48.7 million in the second quarter of 2019, or $0.54 net loss per share. Non-GAAP net loss was $99.2 million, or $0.77 non-GAAP net loss per share, in the second quarter of 2020.

At June 30, 2020, cash, cash equivalents, restricted cash and marketable securities totaled $428.5 million. Net increase in cash, cash equivalents and restricted cash for the quarter was $78.0 million. Cash burn, including various acquisition-related expenses, was $89.2 million for the quarter and $63.8 million when excluding the $25.4 million cash paid to acquire YouScript and Genelex.

Early in the quarter, in response to impacts of the pandemic, the company took actions to significantly scale back operational expenditures. The result of these changes is expected to decrease the discretionary spend in cost of revenue and operating expense beginning in the third quarter.

"We continue to see a solid recovery in volume, improvement in our operating leverage and ability to improve revenue generation. As a result, we are well positioned with sufficient capital to execute our strategy in the coming years," continued Dr. George. "We have added or will be adding important capabilities to our platform through the acquisitions we announced this quarter and our ongoing product development efforts. With our mission clearly in focus, we can continue to navigate these unprecedented times."

Corporate and Scientific Highlights

-- Introduced expanded services and support for transition to telehealth across customer types

-- Launched new capabilities for Gia, the advanced clinical chatbot that became part of Invitae through the acquisition and rapid integration of Clear Genetics. New workflows added to Gia support obstetrician/gynecologists, oncologists, genetic counselors and other clinicians who order genetic testing

-- Increased support for the use of at-home testing using saliva kits, which do not require an in-person clinician visit

-- Provided professional education and support for clinicians transitioning to telehealth

-- Acquired YouScript and Genelex to bring best-in-class pharmacogenetic testing and robust, integrated clinical decision support to Invitae

-- Further expanded international footprint, including the introduction of consumer-initiated telehealth genetic testing services in Canada for carrier testing in early pregnancy and cancer and cardiovascular risk testing

-- Presented research that, combined with new recommendations from a large, multidisciplinary consensus conference published in the Journal of Clinical Oncology, underscores the utility of increased access to genetic testing for men with prostate cancer across all stages of life

-- Added 16 new biopharma partnerships, bringing the total number of partnership programs to more than 105, including nine new pharma partners in Invitae's Detect programs providing no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment

-- Entered into a definitive agreement under which Invitae will combine with ArcherDX, Inc.

-- Closed on a public offering with net proceeds of approximately $173.0 million and raised $44.5 million of net proceeds under the company's ATM

-- In July, added non-invasive prenatal screening (NIPS) based on whole genome sequencing (WGS) to the Invitae platform, providing patients with easier access to affordable genetic testing in early pregnancy to realize cost reductions, improve the company's ability to scale services and pave the way for additional services based on WGS technology

-- Partnered with a major health system to integrate clinical decision support software for use of pharmacogenetics in patient care

Webcast and Conference Call Details Management will host a conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss financial results and recent developments. To register for the conference call and webcast, please use one of the methods below. Upon registering, each participant will be provided with call details and a registrant ID.

Online registration: http://www.directeventreg.com/registration/event/5882896

Phone registration: (888) 869-1189 or (706) 643-5902

The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website.

About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's belief that it is well-positioned to adapt and meet the changing needs of its customers; the company's belief regarding the momentum of its business and ability to continue to deliver on its mission to bring genetic information into mainstream medicine; the impact of the COVID-19 pandemic on the company's business, and the measures it has taken or may take in the future with respect thereto; the impact of the company's acquisitions, including its proposed merger with ArcherDX, as well as its partnerships and product offerings; and the company's beliefs regarding the growth of its business, its position and impact on the genetic testing industry, its success in executing on its mission and strategy, and the benefits of genetic testing. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the impact of the COVID-19 pandemic on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the company's ability to continue to grow its business, including internationally; the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the ability of Invitae and ArcherDX to obtain the approval of Invitae's and ArcherDX's stockholders, and to satisfy the other conditions to the closing of the acquisition and related financing transactions on a timely basis or at all; the occurrence of events that may give rise to a right of one or both of Invitae and ArcherDX to terminate the merger agreement; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Non-GAAP Financial Measures To supplement Invitae's consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), the company is providing several non-GAAP measures, including non-GAAP gross profit, non-GAAP cost of revenue, non-GAAP operating expense, including non-GAAP research and development, non-GAAP selling and marketing, non-GAAP general and administrative and non-GAAP other income (expense), net, as well as non-GAAP net loss and non-GAAP net loss per share and non-GAAP cash burn. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-GAAP financial measures are useful to investors in evaluating the company's ongoing operating results and trends.

Management is excluding from some or all of its non-GAAP operating results (1) amortization of acquired intangible assets, (2) acquisition-related stock-based compensation related to inducement grants, (3) post-combination expense related to the acceleration of equity grants or bonus payments in connection with the company's business combinations, (4) adjustments to the fair value of our acquisition-related liabilities and (5) acquisition-related income tax benefits. These non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in the company's public disclosures.

Cash burn excludes (1) changes in marketable securities, (2) cash received from equity financings and (3) cash received from exercises of warrants. Management believes cash burn is a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. A limitation of using this non-GAAP measure is that cash burn does not represent the total change in cash, cash equivalents, and restricted cash for the period because it excludes cash provided by or used for other operating, investing or financing activities. Management accounts for this limitation by providing information about the company's operating, investing and financing activities in the statements of cash flows in the consolidated financial statements in the company's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase or decrease in cash, cash equivalents and restricted cash in its reconciliation of cash burn.

In addition, other companies, including companies in the same industry, may not use the same non-GAAP measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Because of these limitations, the company's non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the non-GAAP reconciliations provided in the tables below.

INVITAE CORPORATION
Consolidated Balance Sheets
(in thousands)
(unaudited)
                                                    June 30,        December 31,
                                                    2020            2019
Assets
Current assets:
Cash and cash equivalents                           $     168,203   $    151,389
Marketable securities                               253,933         240,436
Accounts receivable                                 27,905          32,541
Prepaid expenses and other current assets           21,081          18,032
Total current assets                                471,122         442,398
Property and equipment, net                         43,381          37,747
Operating lease assets                              38,239          36,640
Restricted cash                                     6,343           6,183
Intangible assets, net                              192,644         125,175
Goodwill                                            211,225         126,777
Other assets                                        6,921           6,681
Total assets                                        $     969,875   $    781,601
Liabilities and stockholders' equity
Current liabilities:
Accounts payable                                    $     20,091    $    10,321
Accrued liabilities                                 99,490          64,814
Operating lease obligations                         6,339           4,870
Finance lease obligations                           977             1,855
Total current liabilities                           126,897         81,860
Operating lease obligations, net of current portion 42,134          42,191
Finance lease obligations, net of current portion   879             1,155
Convertible senior notes, net                       276,092         268,755
Deferred tax liability                              10,250          --
Other long-term liabilities                         49,428          8,000
Total liabilities                                   505,680         401,961
Stockholders' equity:
Common stock                                        13              10
Accumulated other comprehensive income (loss)       572             (9)
Additional paid-in capital                          1,487,217       1,138,316
Accumulated deficit                                 (1,023,607)     (758,677)
Total stockholders' equity                          464,195         379,640
Total liabilities and stockholders' equity          $     969,875   $    781,601
INVITAE CORPORATION
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
                                                    Three Months Ended               Six Months Ended
                                                    June 30,                         June 30,
                                                    2020             2019            2020             2019
Revenue:
Test revenue                                        $    45,099      $    52,302     $    108,177     $    91,921
Other revenue                                       1,092            1,173           2,262            2,107
Total revenue                                       46,191           53,475          110,439          94,028
Cost of revenue                                     42,952           28,006          83,374           49,260
Research and development                            74,963           25,302          130,631          43,296
Selling and marketing                               39,520           30,779          81,640           54,972
General and administrative                          30,838           21,274          54,660           34,593
Loss from operations                                (142,082)        (51,886)        (239,866)        (88,093)
Other income (expense), net                         (21,436)         1,381           (16,728)         2,019
Interest expense                                    (5,485)          (2,121)         (10,936)         (4,229)
Net loss before taxes                               (169,003)        (52,626)        (267,530)        (90,303)
Income tax benefit                                  (2,600)          (3,950)         (2,600)          (3,950)
Net loss                                            $    (166,403)   $    (48,676)   $    (264,930)   $    (86,353)
Net loss per share, basic and diluted               $    (1.29)      $    (0.54)     $    (2.35)      $    (1.01)
Shares used in computing net loss per share, basic  129,023          90,863          112,765          85,148
and diluted
INVITAE CORPORATION
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
                                                                            Six Months Ended June 30,
                                                                            2020             2019
Cash flows from operating activities:
Net loss                                                                    $    (264,930)   $    (86,353)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization                                               14,500           6,725
Stock-based compensation                                                    81,124           19,540
Amortization of debt discount and issuance costs                            7,337            --
Amortization of premium on marketable securities                            --               --
Impairment losses                                                           --               --
Loss on disposal of assets                                                  --               --
Loss on sales of available-for-sale securities                              --               --
Remeasurements of liabilities associated with business combinations         26,749           (286)
Benefit from income taxes                                                   (2,600)          (3,950)
Debt extinguishment costs                                                   --               --
Other                                                                       (536)            1,182
Changes in operating assets and liabilities, net of businesses acquired:
Accounts receivable                                                         4,939            3,153
Prepaid expenses and other current assets                                   (3,049)          (3,825)
Other assets                                                                942              2,410
Accounts payable                                                            9,185            (3,954)
Accrued expenses and other liabilities                                      3,585            4,267
Net cash used in operating activities                                       (122,754)        (61,091)
Cash flows from investing activities:
Purchases of marketable securities                                          (115,350)        (20,781)
Proceeds from sales of marketable securities                                12,532           --
Proceeds from maturities of marketable securities                           89,965           34,000
Acquisition of businesses, net of cash acquired                             (57,576)         3,193
Purchases of property and equipment                                         (10,854)         (8,824)
Other                                                                       (1,334)          --
Net cash provided by (used in) investing activities                         (82,617)         7,588
Cash flows from financing activities:
Proceeds from public offerings of common stock, net                         217,489          184,490
Proceeds from issuance of common stock, net                                 6,760            5,123
Finance lease principal payments                                            (1,154)          (1,031)
Other                                                                       (750)            --
Net cash provided by financing activities                                   222,345          188,582
Net increase in cash, cash equivalents and restricted cash                  16,974           135,079
Cash, cash equivalents and restricted cash at beginning of period           157,572          118,164
Cash, cash equivalents and restricted cash at end of period                 $    174,546     $    253,243
INVITAE CORPORATION
Reconciliation of GAAP to Non-GAAP Cost of Revenue
(in thousands)
(unaudited)
                                            Three Months Ended       Six Months Ended
                                            June 30,                 June 30,
                                            2020         2019        2020         2019
Cost of revenue                             $   42,952   $  28,006   $   83,374   $  49,260
Amortization of acquired intangible assets  (4,757)      (689)       (7,430)      (985)
Non-GAAP cost of revenue                    $   38,195   $  27,317   $   75,944   $  48,275
Reconciliation of GAAP to Non-GAAP Gross Profit
(in thousands)
(unaudited)
                                                   Three Months Ended        Six Months Ended
                                                   June 30,                  June 30,
                                                   2020         2019         2020          2019
Revenue                                            $   46,191   $   53,475   $   110,439   $   94,028
Cost of revenue                                    42,952       28,006       83,374        49,260
Gross profit                                       3,239        25,469       27,065        44,768
Amortization of acquired intangible assets - cost  4,757        689          7,430         985
of revenue
Non-GAAP gross profit                              $   7,996    $   26,158   $   34,495    $   45,753
Reconciliation of GAAP to Non-GAAP Research and Development Expense
(in thousands)
(unaudited)
                                              Three Months Ended         Six Months Ended
                                              June 30,                   June 30,
                                              2020          2019         2020           2019
Research and development                      $    74,963   $   25,302   $    130,631   $   43,296
Amortization of acquired intangible assets    (117)         80           (233)          (233)
Acquisition-related stock-based compensation  (33,383)      (2,586)      (52,182)       (2,586)
Non-GAAP research and development             $    41,463   $   22,796   $    78,216    $   40,477
Reconciliation of GAAP to Non-GAAP Selling and Marketing Expense
(in thousands)
(unaudited)
                                            Three Months Ended        Six Months Ended
                                            June 30,                  June 30,
                                            2020         2019         2020         2019
Selling and marketing                       $   39,520   $   30,779   $   81,640   $   54,972
Amortization of acquired intangible assets  (786)        (675)        (1,571)      (1,349)
Non-GAAP selling and marketing              $   38,734   $   30,104   $   80,069   $   53,623
INVITAE CORPORATION
Reconciliation of GAAP to Non-GAAP General and Administrative Expense
(in thousands)
(unaudited)
                                                           Three Months Ended          Six Months Ended
                                                           June 30,                    June 30,
                                                           2020          2019          2020          2019
General and administrative                                 $    30,838   $    21,274   $    54,660   $    34,593
Amortization of acquired intangible assets                 --            (29)          (10)          (57)
Acquisition-related post-combination expense               (500)         (3,212)       (500)         (3,212)
Fair value adjustments to acquisition-related liabilities  (4,832)       --            (4,832)       --
Non-GAAP general and administrative                        $    25,506   $    18,033   $    49,318   $    31,324
Reconciliation of Operating Expense to Non-GAAP Operating Expense
(in thousands, except per share data)
(unaudited)
                                               Three Months Ended          Six Months Ended
                                               June 30,                    June 30,
                                               2020           2019         2020           2019
Research and development                       $    74,963    $   25,302   $    130,631   $   43,296
Selling and marketing                          39,520         30,779       81,640         54,972
General and administrative                     30,838         21,274       54,660         34,593
Operating expense                              145,321        77,355       266,931        132,861
Amortization of acquired intangible assets     (903)          (624)        (1,814)        (1,639)
Acquisition-related stock-based compensation   (33,383)       (2,586)      (52,182)       (2,586)
Acquisition-related post-combination expense   (500)          (3,212)      (500)          (3,212)
Fair value adjustments to acquisition-related  (4,832)        --           (4,832)        --
liabilities
Non-GAAP operating expense                     $    105,703   $   70,933   $    207,603   $   125,424
Reconciliation of Other Income (Expense), Net to Non-GAAP Other Income (Expense), Net
(in thousands, except per share data)
(unaudited)
                                               Three Months Ended             Six Months Ended
                                               June 30,                       June 30,
                                               2020             2019          2020             2019
Other income (expense), net                    $     (21,436)   $     1,381   $     (16,728)   $     2,019
Fair value adjustments to acquisition-related  25,392           --            21,729           --
liabilities
Non-GAAP other income (expense), net           $     3,956      $     1,381   $     5,001      $     2,019
Reconciliation of Net Loss to Non-GAAP Net Loss Per Share
(in thousands, except per share data)
(unaudited)
                                                Three Months Ended             Six Months Ended
                                                June 30,                       June 30,
                                                2020            2019           2020            2019
Net loss                                        $   (166,403)   $   (48,676)   $   (264,930)   $   (86,353)
Amortization of acquired intangible assets      5,660           1,313          9,244           2,624
Acquisition-related stock-based compensation    33,383          2,586          52,182          2,586
Acquisition-related post-combination expense    500             3,212          500             3,212
Fair value adjustments to acquisition-related   30,224          --             26,561          --
liabilities
Acquisition-related income tax benefit          (2,600)         (3,950)        (2,600)         (3,950)
Non-GAAP net loss                               $   (99,236)    $   (45,515)   $   (179,043)   $   (81,881)
Non-GAAP net loss per share, basic and diluted  $   (0.77)      $   (0.50)     $   (1.59)      $   (0.96)
Shares used in computing net loss per share,    129,023         90,863         112,765         85,148
basic and diluted
INVITAE CORPORATION
Reconciliation of Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash to Cash
Burn
(in thousands)
(unaudited)
                                                      Three Months Ended    Three Months Ended    Six Months Ended
                                                      March 31, 2020        June 30, 2020         June 30, 2020
Net cash used in operating activities                 $         (62,361)    $         (60,393)              (122,754)
Net cash provided by (used in) investing activities   801                   (83,418)                        (82,617)
Net cash provided by financing activities             551                   221,794                         222,345
Net increase (decrease) in cash, cash equivalents and (61,009)              77,983                          16,974
restricted cash
Adjustments:
Purchases of investments                              --                    115,350                         115,350
Sales of investments                                  (12,532)              --                              (12,532)
Maturities of investments                             (24,965)              (65,000)                        (89,965)
Proceeds from public offering of common stock, net    --                    (217,489)                       (217,489)
of issuance costs
Proceeds from exercises of warrants                   (27)                  (35)                            (62)
Cash burn                                             $         (98,533)    $         (89,191)              (187,724)
- Cash burn for the three months ended March 31, 2020 includes $32.3 million of cash paid in connection with the
acquisition of Diploid and cash burn for the three months ended June 30, 2020 includes $25.4 million of cash paid in
connection with the acquisitions of Genelex and YouScript. The change in marketable securities for the six months
ended June 30, 2020 includes unrealized gains of $0.6 million.

Contact:Laura D'Angeloir@invitae.com(628) 213-3369

https://c212.net/c/img/favicon.png?sn=SF82702&sd=2020-08-04

View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-reports-46-2-million-in-revenue-driven-by-more-than-120-000-samples-accessioned-in-the-second-quarter-of-2020--301106028.html

SOURCE Invitae Corporation

https://rt.prnewswire.com/rt.gif?NewsItemId=SF82702&Transmission_Id=202008041605PR_NEWS_USPR_____SF82702&DateId=20200804

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.